



IFW

Docket No. J&J-5092

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Georgios Stamatas, Nikiforos Kollias  
Serial No. : 10/735,188 Art Unit: 3736  
Filed : December 12, 2003 Examiner:  
For : METHOD OF ASSESSING SKIN

I hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope addressed  
to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

June 18, 2004

(Date of Deposit)

William E. McGowan

(Name of applicant, assignee, or Registered Representative)

(Signature)

June 18, 2004

(Date of Signature)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

- ☐ Statement in Accordance with §1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- ☐ Statement in Accordance with §1.97(e) (attached); or

☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☒ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2). (The U.S. patents and each U.S. patent application publication listed on the attached Form PTO-1449 are not enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the

national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i)).

☒ There are no listed references which are not in the English language.

☐ The relevance of those listed references which are not in the English language is as follows:

☒ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/J&J-5092/WEM. This form is submitted in triplicate.

Respectfully submitted,



William E. McGowan  
Reg. No. 39,301  
Attorney for Applicants

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-2197  
DATED: June 18, 2004



PTO/SB/08A (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary) Sheet 1 of 2	<b>Application Number</b>	10/735,188
	<b>Filing Date</b>	12/12/2003
	<b>First Named Inventor</b>	Stamatas
	<b>Group Art Unit</b>	
	<b>Examiner Name</b>	
	<b>Attorney Docket Number</b>	J&J-5092

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		Monnier VM, Kohn RR, Cerami A: Accelerated age-related browning of human collagen in diabetes mellitus. <i>Proc Natl Acad Sci U S A</i> 81(2):583-587, 1984.	
		Doukas AG, Soukos NS, Babusis S, Appa Y, Kollias N: Fluorescence excitation spectroscopy for the measurement of epidermal proliferation. <i>Photochem Photobiol</i> 74(1):96-102., 2001.	
		Gillies R, Zonios G, Anderson RR, Kollias N: Fluorescence excitation spectroscopy provides information about human skin in vivo. <i>J Invest Dermatol</i> 115(4):704-707, 2000.	
		Glueck J. The Climate of Tucson, Arizona. NOAA Technical Memorandum NWS WR-249, Western Region, National Weather Service Office, National Oceanic and Atmospheric Administration, 1997.	
		Hornel SE, Eyre DR: Collagen in the ageing human intervertebral disc: an increase in covalently bound fluorophores and chromophores. <i>Biochim Biophys Acta</i> 1078(2):243-250, 1991.	
		Kato Y, Kawakishi S, Aoki T, Itakura K, Osawa T: Oxidative modification of tryptophan residues exposed to peroxynitrite. <i>Biochem Biophys Res Commun</i> 234(1):82-84, 1997.	
		Kollias N, Gillies R, Moran M, Kochevar IE, Anderson RR: Endogenous skin fluorescence includes bands that may serve as quantitative markers of aging and photoaging. <i>J Invest Dermatol</i> 111(5):776-780, 1998.	
		Leffell DJ, Stetzel ML, Milstone LM, Deckelbaum LI: In vivo fluorescence of human skin. A potential marker of photoaging. <i>Arch Dermatol</i> 124(10):1514-1518, 1988.	
		Monnier VM, Cerami A: Non-enzymatic glycosylation and browning of proteins in diabetes. <i>Clin Endocrinol Metab</i> 11(2):431-452, 1982.	
		Bellmunt MJ, Portero M, Pamplona R, Muntaner M, Prat J: Age-related fluorescence in rat lung collagen. <i>Lung</i> 173(3):177-185, 1995.	
		Brancaleon L, Durkin AJ, Tu JH, Menaker G, Fallon JD, Kollias N: In vivo fluorescence spectroscopy of nonmelanoma skin cancer. <i>Photochem Photobiol</i> 73(2):178-83., 2001	
		Tian, WD, Anderson, R.R., Drake, L.A., Kollias, N., Noninvasive Monitoring of Treatment Related Changes in Psoriatic Plaques Using Fluorescence Excitation and Diffuse Reflectance Spectroscopy, <i>Biomedical Optical Spectroscopy and Diagnostics</i> , 1998 pp. 113-115.	
		Gonzalez, S., Zonios, G., Nguyen, B.C., Gillies, R. Kollias, N. Endogenous Skin Fluorescence is a Good Market for Objective Evaluation of Comedolysis, <i>The Society for Investigative Dermatology, Inc.</i> 2000, pp. 100-105.	
		Kollias, N. and Stamatas, G.N. Optical Non-Invasive Approaches to Diagnosis of Skin Diseases, <i>The Society for Investigative Dermatology, Inc.</i> 2002, pp. 64-75.	
		Brancaleon L, Lin G, Kollias N: The in vivo fluorescence of tryptophan moieties in human skin increases with UV exposure and is a marker for epidermal proliferation. <i>J Invest Dermatol</i> 113(6):977-982, 1999.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Application Number	10/735,188
Filing Date	12/12/2003
First Named Inventor	Stamatas
Group Art Unit	
Examiner Name	
Attorney Docket Number	J&J-5092

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		Monnier VM, Vishwanath V, Frank KE, Elmets CA, Dauchot P, Kohn RR: Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. <i>N Engl J Med</i> 314(7):403-408, 1986.	
		Na R, Stender IM, Henriksen M, Wulf HC: Autofluorescence of human skin is age-related after correction for skin pigmentation and redness. <i>J Invest Dermatol</i> 116(4):536-540, 2001.	
		Njoroge FG, Fernandes AA, Monnier VM: Mechanism of formation of the putative advanced glycosylation end product and protein cross-link 2-(2-furoyl)-4(5)-(2-furanyl)-1H-imidazole. <i>J Biol Chem</i> 263(22):10646-10652, 1988.	
		Odetti P, Pronzato MA, Noverasco G, et al.: Relationships between glycation and oxidation related fluorescences in rat collagen during aging. An in vivo and in vitro study. <i>Lab Invest</i> 70(1):61-67, 1994.	
		Odetti PR, Borgoglio A, Rolandi R: Age-related increase of collagen fluorescence in human subcutaneous tissue. <i>Metabolism</i> 41(6):655-658, 1992.	
		Pongor S, Ulrich PC, Bencsath FA, Cerami A: Aging of proteins: isolation and identification of a fluorescent chromophore from the reaction of polypeptides with glucose. <i>Proc Natl Acad Sci U S A</i> 81(9):2684-2688, 1984.	
		Reihnsner R, Melling M, Pfeiler W, Menzel EJ: Alterations of biochemical and two-dimensional biomechanical properties of human skin in diabetes mellitus as compared to effects of in vitro non-enzymatic glycation. <i>Clin Biomech (Bristol, Avon)</i> 15(5):379-86., 2000.	
		Sell DR, Monnier VM: Structure elucidation of a senescence cross-link from human extracellular matrix. Implication of pentoses in the aging process. <i>J Biol Chem</i> 264(36):21597-21602, 1989.	
		Shaklai N, Garlick RL, Bunn HF: Nonenzymatic glycosylation of human serum albumin alters its conformation and function. <i>J Biol Chem</i> 259(6):3812-3817, 1984.	
		Stamatas GN, Wu J, Kollias N: Non-invasive method for quantitative evaluation of exogenous compound deposition on skin. <i>J Invest Dermatol</i> 118(2):295-302, 2002.	
		Tian WD, Gillies R, Brancalion L, Kollias N: Aging and effects of ultraviolet A exposure may be quantified by fluorescence excitation spectroscopy in vivo. <i>J Invest Dermatol</i> 116(6):840-845, 2001.	
		Wolff SP, Dean RT: Glucose autooxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. <i>Bio000000chem J</i> 245(1):243-250, 1987.	
		Wu J, Feld MS, Rava RP: Analytical model for extracting intrinsic fluorescence in turbid media. <i>Applied Optics</i> 32(19):3585-3595, 1993.	
		Zhang JC, Savage HE, Sacks PG, et al.: Innate cellular fluorescence reflects alterations in cellular proliferation. <i>Lasers Surg Med</i> 20(3):319-31., 1997	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Page 1 of 1

<b>Application Number</b>	10/735,188
<b>Filing Date</b>	12/12/2003
<b>First Named Inventor</b>	Stamatas
<b>Group Art Unit</b>	3736
<b>Examiner Name</b>	
<b>Attorney Docket Number</b>	J&J-5092

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
--------------------	--	-----------------	--